DaVita HealthCare Partners Inc. (NYSE:DVA) – Research analysts at Jefferies Group increased their FY2016 earnings estimates for shares of DaVita HealthCare Partners in a report released on Wednesday. Jefferies Group analyst C. Cooper now anticipates that the brokerage will post earnings per share of $3.59 for the year, up from their previous forecast of $3.56. Jefferies Group also issued estimates for DaVita HealthCare Partners’ FY2017 earnings at $3.64 EPS, FY2018 earnings at $4.26 EPS and FY2019 earnings at $5.04 EPS.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. DaVita HealthCare Partners had a net margin of 4.92% and a return on equity of 16.16%. The company earned $3.73 billion during the quarter, compared to the consensus estimate of $3.72 billion. During the same quarter last year, the firm posted $1.12 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis.

Earnings History and Estimates for DaVita HealthCare Partners (NYSE:DVA)

Other research analysts also recently issued research reports about the stock. SunTrust Banks Inc. set a $66.00 target price on shares of DaVita HealthCare Partners and gave the company a “hold” rating in a research report on Thursday, October 13th. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “strong sell” rating to a “hold” rating in a research report on Friday, November 4th. TheStreet downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Bank of America Corp. downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “neutral” rating and set a $70.00 target price on the stock. in a research report on Tuesday, September 6th. Finally, Citigroup Inc. started coverage on shares of DaVita HealthCare Partners in a report on Tuesday, September 6th. They set a “neutral” rating and a $71.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $75.00.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded down 1.34% on Friday, hitting $61.16. 1,137,870 shares of the stock were exchanged. The stock’s 50-day moving average is $60.82 and its 200-day moving average is $69.79. DaVita HealthCare Partners has a 1-year low of $54.50 and a 1-year high of $78.77. The stock has a market cap of $12.07 billion, a price-to-earnings ratio of 17.83 and a beta of 1.00.

A number of institutional investors have recently bought and sold shares of DVA. Checchi Capital Advisers LLC raised its position in DaVita HealthCare Partners by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 1,556 shares of the company’s stock valued at $120,000 after buying an additional 37 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in DaVita HealthCare Partners during the second quarter valued at $147,000. Mizuho Asset Management Co. Ltd. raised its position in DaVita HealthCare Partners by 78.7% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,191 shares of the company’s stock valued at $169,000 after buying an additional 965 shares during the last quarter. Feltz Wealth PLAN Inc. bought a new position in DaVita HealthCare Partners during the second quarter valued at $186,000. Finally, Global X Management Co. LLC raised its position in DaVita HealthCare Partners by 59.2% in the second quarter. Global X Management Co. LLC now owns 2,422 shares of the company’s stock valued at $187,000 after buying an additional 901 shares during the last quarter. Institutional investors own 83.10% of the company’s stock.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives.

5 Day Chart for NYSE:DVA

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.